Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation
Small Methods · 2025
DOI: 10.1002/smtd.202501401 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Methods, 2025. Verfasst von Cheesue Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Processes, Seoul National University, Seoul, 08826, Republic of Korea. Hauptthemen laut MEDLINE: Nanoparticles, RNA, Messenger, Immunotherapy, Lipids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 217 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Republic of Korea.
Abstract (Originalsprache)
Immunotherapy has transformed therapeutic paradigms, especially in oncology, by leveraging antibodies, cytokines, and cell‐based strategies. In recent years, immunotherapy has expanded its impact to combat a broad spectrum of diseases, including fibrotic, autoimmune, and infectious disorders. Messenger RNA (mRNA)‐based platforms offer distinct advantages for immunotherapy by enabling in vivo synthesis of proteins with native post‐translational modifications to enhance bioactivity and reduce immunogenicity. mRNA also allows non‐viral, transient reprogramming of immune cells in vivo, supporting scalable manufacturing and eliminating the risk of insertional mutagenesis. However, naked mRNA faces clinical limitations including inherent instability, poor cellular uptake, and non‐targeted delivery. Lipid nanoparticles (LNPs) can overcome these challenges by encapsulating mRNA for protected and efficient delivery to target cells. Importantly, recent advances have demonstrated the potential of mRNA‐LNPs to modulate immune cell function with cell‐type specificity, enhancing therapeutic precision. This review highlights progress in engineering mRNA‐LNPs for targeted immune cell delivery, strategies for immune cell‐specific modulation, and applications across immune‐related pathologies. Design considerations to improve delivery efficiency and immunological outcomes are also discussed, supporting the clinical translation of mRNA‐LNP immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Processes, Seoul National University, Seoul, 08826, Republic of Korea.
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea.
- College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.
- School of Transdisciplinary Innovations and College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea.
- Institute of Engineering Research and BioMAX, Seoul National University, Seoul, 08826, Republic of Korea.
ORCID-Profile: Byung-Soo Kim
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT, Republic of Korea
Zitieren
APA
Kim, C., Lee, Y., Lee, H., & Kim, B. S. (2025). Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation. Small Methods. https://doi.org/10.1002/smtd.202501401
Vancouver
Kim C, Lee Y, Lee H, Kim BS. Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation. Small Methods. 2025. doi:10.1002/smtd.202501401
BibTeX
@article{Kim2025,
author = {Kim, Cheesue and Lee, Yeji and Lee, Hyukjin and Kim, Byung-Soo},
title = {Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation},
journal = {Small Methods},
year = {2025},
doi = {10.1002/smtd.202501401}
}
EUVIMED